Form 4: Olema Pharmaceuticals Director J. Scott Garland Granted Stock Options

Olema Pharmaceuticals, Inc. Director J. Scott Garland was granted 24,150 stock options with an exercise price of $4.08, aligning his interests with shareholders.

Summary

• J. Scott Garland, a Director of Olema Pharmaceuticals, Inc. (OLMA), was granted stock options.
• The transaction date for the option grant was June 11, 2025.
• The stock option allows the right to buy 24,150 shares of Common Stock.
• The exercise price for these options is $4.08 per share.
• The options have an expiration date of June 11, 2035.
• The shares subject to the option will vest in 12 successive equal monthly installments, starting from June 11, 2025.
• Vesting is contingent upon Mr. Garland's continuous service to the company through each applicable vesting date.
• The options will fully vest on the date of the Issuer's next annual meeting of stockholders if not already fully vested by that date, also subject to continuous service.
• Following this transaction, Mr. Garland beneficially owns 24,150 derivative securities (stock options) directly.

Sentiment

Score: 7

Explanation: The sentiment is moderately positive. While a Form 4 is a routine disclosure, the grant of options to a director aligns their interests with shareholders and can be seen as a positive signal of commitment and confidence in the company's future.

Positives

• The grant of stock options to a director aligns their financial interests with those of the shareholders, incentivizing long-term company performance.
• The acquisition of options by a director can signal confidence in the company's future prospects.

Future Outlook

The vesting schedule indicates an expectation of J. Scott Garland's continued service as a Director for at least the next 12 months, or until the next annual meeting of stockholders, to fully realize the benefit of the option grant.

Management Comments

• The shares subject to the option vest in a series of 12 successive equal monthly installments measured from June 11, 2025, subject to the Reporting Person's continuous service through each applicable vesting date.
• Such shares vest in full on the date of the Issuer's next annual meeting of stockholders if such stock option is not otherwise fully vested by such date, subject to the Reporting Person's continuous service through such vesting date.

Industry Context

The granting of stock options to directors is a common practice in the biotechnology and pharmaceutical industries, as well as across publicly traded companies, to attract and retain talent, and to align the interests of leadership with long-term shareholder value creation.

Comparison to Industry Standards

• The grant of stock options as part of director compensation is a standard practice across publicly traded companies, including those in the biotechnology sector like Olema Pharmaceuticals.
• The vesting schedule, tied to continuous service and potential acceleration at the next annual meeting, is a typical structure for such equity awards, comparable to compensation packages seen at companies like Moderna, BioNTech, or Gilead Sciences for their non-executive directors, though specific values and terms vary by company size and individual contribution.

Corporate Governance

Related Party Transactions

• The grant of stock options to J. Scott Garland, a Director of Olema Pharmaceuticals, Inc., constitutes a transaction with a related party as part of his compensation.

Stakeholder Impact

• Shareholders: The grant aligns the director's interests with shareholders, potentially leading to better long-term performance and governance.
• Employees: No direct impact on general employees is indicated by this specific filing.

Next Steps

• J. Scott Garland's continued service to Olema Pharmaceuticals, Inc. to fulfill the vesting conditions of the stock options.

Key Dates

Keywords

Olema Pharmaceuticals, OLMA, Stock Option, Director Compensation, Insider Transaction, Equity Grant, SEC Form 4, Corporate Governance